Updates are available Correction dated 2021-08-09
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s12931-021-01803-y
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02497001 at ClinicalTrials.govDocuments that mention this clinical trial
S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study
https://0-doi-org.brum.beds.ac.uk/10.1136/thorax-2021-btsabstracts.110
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
https://0-doi-org.brum.beds.ac.uk/10.1186/s12931-021-01773-1
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 7 April 2021
Accepted: 6 June 2021
First Online: 28 June 2021
Change Date: 9 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s12931-021-01803-y
Declarations
:
: This study was done in accordance with Good Clinical Practice, including the Declaration of Helsinki. The protocol and informed consent form were approved by appropriate institutional review boards or independent ethics committees [CitationRef removed]. All patients provided written informed consent before screening.
: Not applicable.
: SM has received lecture fees from AstraZeneca, GSK, Nippon Boehringer Ingelheim, and Novartis Pharma. HS has received lecture fees from AstraZeneca, GSK, Nippon Boehringer Ingelheim, and Novartis Pharma. PDo is an employee of AstraZeneca and holds stock and/or stock options in the company. PDa is an employee of AstraZeneca and holds stock and/or stock options in the company.
